M&A Opportunity Recently acquired by BD, TVA Medical may benefit from BD’s global sales and distribution network to expand reach into dialysis centers and vascular access markets.

Endovascular Focus Specialization in everlinQ endovascular arteriovenous fistula systems for hemodialysis presents a clear cross-sell with BD’s large portfolio of vascular access and interventional products.

Early Stage Growth With modest employee count and revenue in the high six digits to low tens of millions, there is room to accelerate market penetration through BD-backed resources, clinical partnerships, and payer engagement.

Data Driven Recent meta-analysis data showcasing high procedure success and fistula maturation provides ammunition for clinical partnerships, reimbursement tactics, and site adoption programs.

Global Expansion Leverage BD’s international footprint to introduce minimally invasive therapies for end-stage renal disease into new geographies, targeting hospitals, surgery centers, and endovascular suites.